An observational study in Post Procedural Erythema, sponsored by Acorn Biolabs Inc.. Recruiting at 42 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Acorn Biolabs Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.
Among the 55 studies in Erythema with a site in United States, this one is one of 3 that started in 2024, is one of 3 observational ones, and was the 50th registered.
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:
Medicines Development for Global Health · Sites in United States, Benin, Côte D'Ivoire and 3 more countries
Ages 18+
Good Molecules, LLC · Sites in United States
Ages 18–75 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
Sun Protection Foundation · Sites in United States, Chile, Peru
Ages 15–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 40 across 11 observational studies indexed under Erythema.
Median enrollment 52 across the 52 interventional studies, 104 across the 3 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 55 have an industry lead sponsor. The 10 most frequent:
Acorn Biolabs Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Acorn Biolabs Inc. has 1 study filed under Erythema — fewer than ten, so there is no comparison to draw.
4 of the studies in Erythema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172659Medicines Development for Global HealthEfficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction | 2027-01 |
| NCT06477172Acorn Biolabs Inc.Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures | 2027-02 |
| NCT07789639Good Molecules, LLCA Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use | 2027-02-24 |
| NCT02876107M.D. Anderson Cancer CenterCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Erythema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.
This non-interventional, observation study is to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product following various medical aesthetic procedures.
The study population will be patients planning a medical aesthetic procedure and use of Autologous Hair Follicle Secretome cosmetic post-procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects receiving hair procedures (closed to enrollment):
Undergoing one of the following medical aesthetic procedures:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Post-Procedure Symptoms
Symptoms of redness, swelling, oozing, pain, tenderness, crusting, itching and discoloration will be measured using a 1-10 likert scale with 0 being best possible and 10 being worst imaginable.
Time frame: 1-7 days
Downtime Questionnaire
Questionnaire asking what activities would they have done, if it were not for their face appearance. Date of end of downtime captured.
Time frame: 1-7 days
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acorn Biolabs Inc.